GEN İlaç Chairman: Innovative Drug from Turkey Could Exceed $1 Billion
Abidin Gülmüş, Chairman of GEN İlaç, made statements about the pharmaceutical sector on the program 'Health on the Stock Exchange' broadcast on Dünya Gazetesi TV. Gülmüş emphasized that artificial intelligence accelerates drug development processes, noting that Turkey has achieved significant localization in drug production, but the main goal is to develop high value-added innovative products.
Gülmüş stated that an innovative drug emerging from Turkey could surpass the $1 billion threshold. He reported that the company is conducting clinical studies for Parkinson's and Alzheimer's treatments and has made significant progress in these areas.
Additionally, Gülmüş shared international growth targets with a new production facility to be established in Azerbaijan, saying this investment will increase the company's competitiveness in the global market. GEN İlaç continues to strengthen its local production capacity while accelerating its innovative drug development efforts.
This is not investment advice.
The news creates a positive outlook for GENIL's innovative drug potential. However, technical indicators are weak: RSI at 46 is in neutral territory, MACD is below the signal line, and the price is below the 20- and 50-day moving averages. In the short term, this positive news may trigger a limited rally constrained by technical resistance. Still, given the low momentum, a sustained uptrend appears unlikely.
The news creates a positive outlook for GEN İlaç's innovative drug potential. Technical indicators support this optimism: the RSI at 64 is not yet in overbought territory, the MACD is above its signal line and positive, and the price is above both the 20-day and 50-day moving averages. The 5.3% gain in the last session indicates strong momentum. However, it may be too early to expect an extreme short-term move, so I foresee a moderately confident upside impact.
